This manuscript highlights some successful applications of bringing MIPD to clinical care and proposes strategies for wider integration of MIPD in healthcare.
Considerations are brought up herein that will need addressing to see MIPD become ‘widespread clinical practice': amongst those, wider interdisciplinary collaborations and the necessity for further evidence-based efficacy and cost-benefit analysis of MIPD in healthcare. The implications of MIPD on regulatory policies and pharmaceutical development are also discussed as part of the roadmap
FingerprintDive into the research topics of 'Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future'. Together they form a unique fingerprint.
Impact: Technological impacts, Economic, Health and wellbeing, Policy